HTG Molecular Diagnostics, Inc. develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's assay product offerings include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq PATH Assay; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq EGFR, KRAS, and BRAF mutation assay; HTG EdgeSeq ALKPlus assay EU; and HTG EdgeSeq DLBCL cell of origin assay EU. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a collaboration agreement with Bristol-Myers Squibb for the development of custom RUO assays; master collaboration agreement with Merck KGaA; governing agreement with QIAGEN Manchester Limited; and development and professional services agreement with Invetech PTY Ltd. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HTGM
Previous Symbol
CUSIPN/A
Phone877-289-2615
Debt
Debt-to-Equity Ratio0.42
Current Ratio7.13
Quick Ratio6.93
Price-To-Earnings
Trailing P/E Ratio-1.73
Forward P/E Ratio-4.43
P/E GrowthN/A
Sales & Book Value
Annual Sales$14.76 million
Price / Sales5.99
Cash FlowN/A
Price / CashN/A
Book Value($0.12) per share
Price / Book-25.83
Profitability
EPS (Most Recent Fiscal Year)($1.79)
Net Income$-18,960,000.00
Net Margins-74.94%
Return on Equity-83.42%
Return on Assets-38.57%
Miscellaneous
Employees98
Outstanding Shares28,500,000
Market Cap$98.31 million
OptionableOptionable
HTG Molecular Diagnostics (NASDAQ:HTGM) Frequently Asked Questions
What is HTG Molecular Diagnostics' stock symbol?
HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."
How were HTG Molecular Diagnostics' earnings last quarter?
HTG Molecular Diagnostics Inc (NASDAQ:HTGM) posted its quarterly earnings data on Thursday, November, 8th. The medical research company reported ($0.17) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.18) by $0.01. The medical research company earned $4.71 million during the quarter, compared to the consensus estimate of $5.14 million. HTG Molecular Diagnostics had a negative net margin of 74.94% and a negative return on equity of 83.42%. View HTG Molecular Diagnostics' Earnings History.
When is HTG Molecular Diagnostics' next earnings date?
What guidance has HTG Molecular Diagnostics issued on next quarter's earnings?
HTG Molecular Diagnostics updated its FY 2018 earnings guidance on Thursday, November, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $21-25 million, compared to the consensus revenue estimate of $21.64 million.
What price target have analysts set for HTGM?
5 analysts have issued 12 month target prices for HTG Molecular Diagnostics' shares. Their forecasts range from $7.00 to $8.00. On average, they anticipate HTG Molecular Diagnostics' share price to reach $7.50 in the next year. This suggests a possible upside of 144.3% from the stock's current price. View Analyst Price Targets for HTG Molecular Diagnostics.
What is the consensus analysts' recommendation for HTG Molecular Diagnostics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HTG Molecular Diagnostics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for HTG Molecular Diagnostics.
What are Wall Street analysts saying about HTG Molecular Diagnostics stock?
Here are some recent quotes from research analysts about HTG Molecular Diagnostics stock:
- 1. According to Zacks Investment Research, "HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. " (11/15/2018)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and 12-month price target of $7 on shares of HTGM. HTG reported 3Q18 revenue of $4.7MM (+26%), $0.4MM below FactSet consensus. Product and service RUO revenue was lighter than our expectations, but was offset by strong revenue from Collaboration Agreements. HTG expects to achieve the midpoint of its previously indicated 2018 revenue guidance ($21-25MM), implying 17% top-line growth in 4Q. We think momentum is starting to pick up for HTG with a number of drivers in the business expected to materialize in late 2018 into 2019." (11/9/2018)
- 3. HC Wainwright analysts commented, "As we roll forward the DCF analysis, our estimated market value of the firm has increased from $192M to $200M. Assuming 28.5M shares outstanding as of end-3Q19, this translates to a per share value of about $7, the same as previously." (9/28/2018)
Has HTG Molecular Diagnostics been receiving favorable news coverage?
Headlines about HTGM stock have been trending somewhat positive this week, according to InfoTrie. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. HTG Molecular Diagnostics earned a news impact score of 1.0 on InfoTrie's scale. They also assigned news articles about the medical research company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near term.
Who are some of HTG Molecular Diagnostics' key competitors?
Who are HTG Molecular Diagnostics' key executives?
HTG Molecular Diagnostics' management team includes the folowing people:
- Mr. Timothy B. Johnson, CEO & Director (Age 57)
- Mr. John L. Lubniewski, Pres & COO (Age 54)
- Mr. Shaun D. McMeans, Sr. VP, CFO, Sec. & Treasurer (Age 56)
- Dr. Debra A. Gordon, Sr. VP and Chief Legal Counsel (Age 58)
- Dr. Patrick C. Roche, Sr. VP of R&D (Age 65)
When did HTG Molecular Diagnostics IPO?
(HTGM) raised $50 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 3,600,000 shares at $13.00-$15.00 per share. Leerink Partners served as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.
Who are HTG Molecular Diagnostics' major shareholders?
HTG Molecular Diagnostics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (12.63%), Putnam Investments LLC (3.69%), Private Wealth Partners LLC (3.52%), Stonepine Capital Management LLC (1.88%), Russell Investments Group Ltd. (0.76%) and Granite Point Capital Management L.P. (0.70%). Company insiders that own HTG Molecular Diagnostics stock include Holdings A/S Novo, Plc Glaxosmithkline and Shaun D Mcmeans. View Institutional Ownership Trends for HTG Molecular Diagnostics.
Which institutional investors are selling HTG Molecular Diagnostics stock?
Which institutional investors are buying HTG Molecular Diagnostics stock?
HTGM stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Granite Point Capital Management L.P., FMR LLC, Private Wealth Partners LLC, Symmetry Peak Management LLC and Virtu Financial LLC. View Insider Buying and Selling for HTG Molecular Diagnostics.
How do I buy shares of HTG Molecular Diagnostics?
Shares of HTGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is HTG Molecular Diagnostics' stock price today?
One share of HTGM stock can currently be purchased for approximately $3.07.
How big of a company is HTG Molecular Diagnostics?
HTG Molecular Diagnostics has a market capitalization of $98.31 million and generates $14.76 million in revenue each year. The medical research company earns $-18,960,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis. HTG Molecular Diagnostics employs 98 workers across the globe.
What is HTG Molecular Diagnostics' official website?
How can I contact HTG Molecular Diagnostics?
HTG Molecular Diagnostics' mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The medical research company can be reached via phone at 877-289-2615.
MarketBeat Community Rating for HTG Molecular Diagnostics (NASDAQ HTGM)
MarketBeat's community ratings are surveys of what our community members think about HTG Molecular Diagnostics and other stocks. Vote "Outperform" if you believe HTGM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HTGM will underperform the S&P 500 over the long term. You may vote once every thirty days.
